Medication info
Linawon Duo Tablets 2.5/850 mg (Linagliptin, Metformin)

Linawon Duo Tablets 2.5/850 mg (Linagliptin, Metformin)

Prescription medicationTabletOral
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›850mg / 1 tablet
Manufacturer / importer
Hana Pharmaceutical Co., Ltd.
Appearance
Bright orange, biconvex, oval film-coated tablet
Packaging
30 tablets/bottle, 60 tablets/bottle, 100 tablets/bottle, 200 tablets/bottle
Approval status
Active

MFDS item code 201903533 · Approved 2019.05.29 · Insurance code 657808110

Summary

Main use
Improves blood glucose control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this drug should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended dose of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This drug is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no previous experience with antidiabetic drug therapy whose blood glucose cannot be adequately controlled with monotherapy, the initial dose is 1 tablet of this drug 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this drug 2.5/1000 mg twice daily. 2. Patients whose blood glucose cannot be adequately controlled with metformin monotherapy: The initial dose of this drug should provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient’s previous metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this drug should start at their previous doses of linagliptin and metformin. 4. Patients whose blood glucose cannot be adequately controlled with combination therapy with metformin and a sulfonylurea: The initial dose of this drug should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient’s previous metformin dose. When this drug is administered in combination with a sulfonylurea, the sulfonylurea dose may need to be reduced to lower the risk of hypoglycemia (see Precautions, 3. Administration with caution in the following patients). 5. Patients whose blood glucose cannot be adequately controlled with combination therapy with insulin and metformin: The initial dose of this drug should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient’s previous metformin dose. When this drug is administered in combination with insulin, the insulin dose may need to be reduced to lower the risk of hypoglycemia (see Precautions, 3. Administration with caution in the following patients). No studies have evaluated the safety and efficacy of switching to this drug in patients previously treated with other oral antihyperglycemic agents. Any change in the treatment regimen for type 2 diabetes may alter blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This drug may be used, with the following dose adjustment, in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis. Treatment should not be initiated with this drug because the starting dose of metformin is 500mg or 850mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because it contains metformin (see Precautions, 2. Do not administer to the following patients).

Ingredients

Manufacturer
Hana Pharmaceutical Co., Ltd.

Efficacy & effects

Improves blood glucose control in patients with type 2 diabetes mellitus

View approved original text

This medication is used in conjunction with dietary and exercise therapy to assist in blood sugar control for patients with type 2 diabetes. The combined action of linagliptin and metformin helps effectively regulate blood sugar levels. This contributes to the improvement of blood sugar levels and diabetes management. Patients who take this medication consistently will find significant help in improving blood sugar control.

How to take

Adult dose

The dose of this drug should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended dose of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This drug is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no previous experience with antidiabetic drug therapy whose blood glucose cannot be adequately controlled with monotherapy, the initial dose is 1 tablet of this drug 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this drug 2.5/1000 mg twice daily. 2. Patients whose blood glucose cannot be adequately controlled with metformin monotherapy: The initial dose of this drug should provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient’s previous metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this drug should start at their previous doses of linagliptin and metformin. 4. Patients whose blood glucose cannot be adequately controlled with combination therapy with metformin and a sulfonylurea: The initial dose of this drug should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient’s previous metformin dose. When this drug is administered in combination with a sulfonylurea, the sulfonylurea dose may need to be reduced to lower the risk of hypoglycemia (see Precautions, 3. Administration with caution in the following patients). 5. Patients whose blood glucose cannot be adequately controlled with combination therapy with insulin and metformin: The initial dose of this drug should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient’s previous metformin dose. When this drug is administered in combination with insulin, the insulin dose may need to be reduced to lower the risk of hypoglycemia (see Precautions, 3. Administration with caution in the following patients). No studies have evaluated the safety and efficacy of switching to this drug in patients previously treated with other oral antihyperglycemic agents. Any change in the treatment regimen for type 2 diabetes may alter blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This drug may be used, with the following dose adjustment, in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis. Treatment should not be initiated with this drug because the starting dose of metformin is 500mg or 850mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because it contains metformin (see Precautions, 2. Do not administer to the following patients).

Precautions

This medication helps regulate blood sugar levels. However, there is a risk of developing a rare complication known as lactic acidosis during treatment, so caution is required. Patients with allergies to any of the ingredients, type 1 diabetes, or severe renal impairment should not take this medication. Furthermore, patients who are dehydrated, have severe infections, or have poor heart or liver function should avoid this medication. Symptoms of hypoglycemia may occur, so especially when taken with insulin or sulfonylurea medications, blood sugar levels should be monitored regularly. Patients with impaired kidney function should undergo renal function tests before taking this medication and should have regular check-ups. If facing an acute illness or undergoing surgery, the medication should be temporarily discontinued. While taking this medication, gastrointestinal disorders such as abdominal pain, vomiting, and diarrhea may appear, and in rare cases, acute pancreatitis or blistering similar to bullous pemphigoid may occur, so if these symptoms arise, consultation with a doctor is necessary. It is advisable for women who are pregnant or breastfeeding to avoid this medication, and it is not recommended for children under 10 years old and adolescents between 10 and 17 years old. Elderly patients should have their renal function monitored regularly and should start at the minimum dosage, as renal function decline is common in this age group. This medication may interact with other drugs, so if currently taking any medications, patients must inform their doctor or pharmacist. Alcohol consumption should be avoided as it may increase the risk of lactic acidosis. When storing this medication, keep it out of reach of children and protect it from moisture. In case of overdose, immediate medical attention is required, and hemodialysis may be necessary.

Side effects

  • lactic acidosis
  • pharyngitis
  • hypersensitivity
  • angioedema
  • urticaria
  • vitamin B12 reduction and deficiency
  • hypoglycemia
  • taste disorder
  • cough
  • decreased appetite
Show 106 more
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
  • abdominal pain
  • oral ulcer formation
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rash
  • blistering pemphigoid
  • severe and debilitating arthralgia
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • constipation
  • epigastric pain
  • enterocolitis
  • intestinal obstruction
  • gastroenteritis
  • herpes zoster
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • decreased appetite
  • dehydration
  • hyperglycemia
  • cerebral infarction
  • speech disorders
  • Alzheimer's dementia
  • chest pain
  • fever
  • facial edema
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot
  • skin lesions
  • liver metastasis
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • stomach cancer
  • rectal cancer
  • pancreatic cancer
  • meniscus injury
  • pneumoconiosis
  • congestive heart failure
  • angina pectoris
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage renal disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • dizziness
  • kidney transplant failure
  • anxiety
  • mood disorders
  • insomnia
  • depression
  • contusion
  • bone contusion
  • concussion
  • bone fracture
  • hand fracture
  • laceration
  • palpitations
  • dry eye
  • cataract
  • ocular discomfort
  • allergic conjunctivitis
  • polyuria
  • hematuria
  • hypotension
  • flushing
  • fatty liver disease
  • cholelithiasis
  • hearing loss
  • erectile dysfunction
  • goiter
  • anemia
  • dizziness
  • sensory loss
  • chest discomfort
  • weakness
  • nosebleed
  • oropharyngeal pain
  • voice disorders
  • epistaxis
  • benign prostatic hyperplasia
  • pruritus
  • insomnia
  • hypertension
  • delirium
  • nocturia
  • dermatitis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so the bottle should be tightly closed and stored in an airtight condition. It is best to store it at room temperature, avoiding extreme heat or cold, specifically between 1 degree and 30 degrees Celsius.

Appearance and packaging

Appearance

Bright orange, biconvex, oval film-coated tablet

Package unit

30 tablets/bottle, 60 tablets/bottle, 100 tablets/bottle, 200 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.